Anyone who thought Gilead Sciences Inc. had the hepatitis C virus (HCV) market sewn up with the December 2013 FDA approval of once-daily oral nucleotide analogue sofosbuvir, branded Sovaldi, isn’t taking the long view. Sovaldi is off to a roaring start but, as Leerink Partners LLC analyst Howard Liang observed in a recent HCV industry update, “by our count there are a total of 19 interferon (IFN)-free regimens for which some sustained virological response (SVR, viral cure) data are available.” Read More
Last week, Cambridge, Mass.-based Aveo Oncology and Astellas Pharma Inc., of Tokyo, announced that they were discontinuing a Phase II trial testing tivozanib in patients with locally recurrent or metastatic triple negative breast cancer due to insufficient enrollment. Read More
It may sound like a broken record, but the biotech sector is still on an incredible roll and has started out the New Year the way it ended 2013, pushing its collective valuation to even new record highs. Read More
